VAXXIT

VAXXIT is an innovative early-stage company based in Rome, Italy, with a focus on developing TatImmune®, a novel phase III-stage immunotherapy for HIV/AIDS, along with preclinical vaccines for Herpes Simplex Virus (HSV) and M. Tuberculosis (TB). The company holds patents for TatImmune in the USA, Europe, and South Africa, with pending patent applications for HSV and TB vaccine candidates in Europe. VAXXIT is currently seeking EUR 10 million in its Series A round to fund TatImmune licensure studies in RSA and establish a senior management team. Additionally, a EUR 15 million Series B round is planned for financing clinical development in Europe and the USA after the phase III trial endpoints are met in RSA. Founded in July 2012, VAXXIT operates primarily through outsourcing and research and commercial collaborations. The company's operating costs mainly consist of patenting costs and government taxes. Dr. Giovanni Cozzone, the co-founder and CEO, leads the operations with the support of senior scientists and industry professionals with over 200 years of aggregate experience in vaccine development. VAXXIT is involved in various collaborations, including grant applications with European and Italian research partners, clinical research through the TV PPP-004 consortium in South Africa, and support from the Tat Vaccine Partnership for soliciting international foundations. The company also collaborates with Diatheva Srl for GMP Manufacturing and has garnered interest from a leading producer and distributor of ART regimens worldwide for marketing and distribution. Overall, VAXXIT presents an innovative approach to HIV therapy and has strategically positioned itself for significant advancements in the field of immunotherapy. The company's collaborations and strong leadership reflect a promising trajectory for potential investors and commercial partners.